{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347400","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-08-12T23:35:50+00:00","discovered_at":"2026-08-13T10:05:00.695199+00:00","generated_at":"2026-08-13T10:05:31.353716+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cullinan's zipalertinib combo meets PFS endpoint in Phase 3 REZILIENT3 trial","bullets":["REZILIENT3 Phase 3 trial (285 patients) met primary endpoint of PFS at planned interim analysis; statistically significant and clinically meaningful improvement.","Zipalertinib plus platinum-based chemotherapy vs chemo alone in first-line EGFR exon 20 insertion NSCLC; safety manageable.","Independent Data Monitoring Committee recommended unblinding; trial continues for efficacy/safety monitoring.","Taiho and Cullinan plan to pursue U.S. FDA approval for the combination in first-line setting pending discussions.","Full results to be submitted for presentation at an upcoming international medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347400","json":"https://secwatch.observer/filing/0001193125-26-347400.json","markdown":"https://secwatch.observer/filing/0001193125-26-347400.md","text":"https://secwatch.observer/filing/0001193125-26-347400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526347400/0001193125-26-347400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526347400/cgem-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T10:05:31.353716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}